Evidence map›Paper›PMID 29229598›Full record

ArticleCancer research2018

Mayur A Gadhikar, Jiexin Zhang, Li Shen, Xiayu Rao, Jing Wang, Mei Zhao, Nene N Kalu, Faye M Johnson, Lauren A Byers, John Heymach and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Cancers · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Mayur A GadhikarDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
Jiexin ZhangDepartment of Biostatistics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Li ShenDepartment of Biostatistics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Xiayu RaoDepartment of Biostatistics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Jing WangDepartment of Biostatistics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Mei ZhaoDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
Nene N KaluThoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Faye M JohnsonThoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lauren A ByersThoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
John HeymachThoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Walter N HittelmanDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Houston, Texas.
Durga UdayakumarDepartment of Radiation Oncology, Institute for Academic Medicine, Houston Methodist, Houston, Texas.
Raj K PanditaDepartment of Radiation Oncology, Institute for Academic Medicine, Houston Methodist, Houston, Texas.
Tej K PanditaDepartment of Radiation Oncology, Institute for Academic Medicine, Houston Methodist, Houston, Texas.
Curtis R PickeringDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abena B RedwoodDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Helen Piwnica-WormsDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Katharina SchlacherDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Mitchell J Frederick *Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, Texas. jmyers@mdanderson.org Mitchell.Frederick@bcm.edu.
Jeffrey N Myers *Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. jmyers@mdanderson.org Mitchell.Frederick@bcm.edu.
The University of Texas MD Anderson Cancer Center · USHouston Methodist · USBaylor College of Medicine · US

Funding

Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
Progression of Metastasis of Oral Tongue CancerR01DE014613 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2003 to 2018
$5.4M
Translating genomic alterations into novel therapeutic targets in head and neck cancer through computational and functional approachesU01DE025181 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FREDERICK, MITCHELL J., LICHTARGE, OLIVIER · 2015 to 2018
$3.8M
CHROMATIN MODIFYING FACTORS CONTROL RADIATION RESPONSE AND GENOMIC STABILITYR01CA129537 · NCI · WASHINGTON UNIVERSITY · PI PANDITA, TEJ K · 2008 to 2018
$3.3M
Predicting and overcoming chemoradioresistance in p53-mutant head and neck cancerR01DE024601 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2014 to 2018
$2.6M
Role of Heterochromatin protein 1 Beta in Genome Maintenance and OncogenesisR01GM109768 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI PANDITA, TEJ K · 2014 to 2017
$1.2M
NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA129537NIDCR NIH HHS R01 DE014613NIDCR NIH HHS R01 DE024601NIDCR NIH HHS U01 DE025181NIGMS NIH HHS R01 GM109768
6 · The paper itself

Abstract

Checkpoint kinase inhibitors (CHKi) exhibit striking single-agent activity in certain tumors, but the mechanisms accounting for hypersensitivity are poorly understood. We screened a panel of 49 established human head and neck squamous cell carcinoma (HNSCC) cell lines and report that nearly 20% are hypersensitive to CHKi monotherapy. Hypersensitive cells underwent early S-phase arrest at drug doses sufficient to inhibit greater than 90% of CHK1 activity. Reduced rate of DNA replication fork progression and chromosomal shattering were also observed, suggesting replication stress as a root causative factor in CHKi hypersensitivity. To explore genomic underpinnings of CHKi hypersensitivity, comparative genomic analysis was performed between hypersensitive cells and cells categorized as least sensitive because they showed drug IC

Indexed as

S PhaseAntineoplastic AgentsApoptosisBiomarkers, TumorCarcinoma, Squamous CellCell ProliferationCheckpoint Kinase 1Cyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18DNA ReplicationEnzyme ActivationEnzyme InhibitorsHead and Neck NeoplasmsHumansSequence DeletionAntineoplastic AgentsBiomarkers, TumorCDK2 protein, humanCDKN2A protein, humanCheckpoint Kinase 1CHEK1 protein, humanCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Enzyme Inhibitors

Identifiers

PMID29229598
PMCPMC5811346
OpenAlexW2772130247

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.